AI assistant
Sending…
Cardiff Oncology, Inc. — Director's Dealing 2021
Jun 14, 2021
33967_dirs_2021-06-14_cab9f477-2129-47f5-bb8c-0ad2c17dc2bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-06-10
Reporting Person: TANNENBAUM RENEE P (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-10 | Stock Options | $7.98 | A | 44001 | Acquired | 2031-06-10 | Common Stock (44001.0) | Direct |
Footnotes
F1: 14,667 vest on 6/10/2022, 6/10/2023, and 6/20/2024
More from Cardiff Oncology, Inc.
Investor Presentation
2026
Jun 3
Legal Proceedings Report
2026
May 29
Legal Proceedings Report
2026
May 19
Earnings Release
2026
May 14
Interim / Quarterly Report
2026
May 14
Board/Management Information
2026
Apr 9
Investor Presentation
2026
Feb 25
Earnings Release
2026
Feb 24
Annual Report
2026
Feb 24
Director's Dealing
2026
Feb 18